New York

Overview

New York legalized adult-use cannabis on March 31, 2021 via the Marijuana Regulation and Taxation Act (MRTA), signed by Governor Andrew Cuomo as Chapter 92 of 2021. The state's medical cannabis program, originally established by the Compassionate Care Act of 2014, was substantially expanded by MRTA and by Office of Cannabis Management (OCM) rulemaking, most notably through the 2022 shift to practitioner discretion for patient certification.

Both programs are governed by New York Cannabis Law Article 4 and Public Health Law Article 33-A, with regulation by the Office of Cannabis Management and the Cannabis Control Board.

Adult-use

• Public possession: up to 3 ounces of cannabis flower; 24 g (0.85 oz) of concentrate.
• In-residence: up to 5 pounds at home.
• Home cultivation: 6 plants per adult (3 mature, 3 immature); maximum 12 per household. Adult-use cultivation rights became effective approximately 18 months after retail sales began (~June 2024).
• Penalties over-limit: 3–16 oz violation ($150); 16 oz – 5 lb misdemeanor (up to 1 yr, $1,000); 5–10 lb felony (4 yrs, $5,000); 10+ lb felony (7 yrs, $10,000).

Medical program

Practitioner-discretion certification (2022 expansion)

The 2022 OCM expansion replaced the pre-2022 enumerated qualifying-conditions list with practitioner discretion: any registered physician, nurse practitioner, or physician assistant may certify a patient if they reasonably believe the patient would benefit from medical cannabis. This is the most permissive certification standard among US medical-cannabis programs.

The list of historically explicitly recognized conditions (cancer, HIV/AIDS, ALS, Parkinson's, MS, neuropathies, IBD, epilepsy, chronic pain, PTSD, and others) remains common in practice, but the formal certifying authority now rests with the practitioner's clinical judgment.

Patient access

• Possession: 60-day supply as determined by the certifying practitioner.
• Approved forms: flower, oils, tinctures, capsules, edibles, vapes, topicals.
• Home cultivation: allowed for patients on the same terms as adult-use (6 plants per adult).
• Reciprocity: non-resident medical cardholders may purchase from New York medical dispensaries via OCM reciprocity policy. Verify current restrictions.

Patients and caregivers

• Patient minimum age: 18. Minor patients under 18 may access medical cannabis only through a designated caregiver (parent or legal guardian) with practitioner certification.
• Caregiver minimum age: 21.
• Caregivers per patient: up to 2 designated individual caregivers per patient (verify current OCM rule).
• Caregiver registration: via OCM registry; criminal background check. A caregiver may not consume the patient's cannabis unless the caregiver is also a registered patient.

Patient registration steps

1. Locate an OCM-registered practitioner (physician, nurse practitioner, or physician assistant) willing to certify cannabis use. The OCM directory lists registered practitioners; the practitioner must complete a four-hour training course and register with the program.
2. The practitioner issues a certification through the Office of Cannabis Management Medical Cannabis Program portal.
3. The patient registers online through the OCM portal, submits identity documents, proof of New York residency, and a current photo. The standard registration fee is $50; reduced fees apply for veterans, seniors, and patients receiving Medicaid or SSI.
4. Approved patients receive a registry ID that authorizes purchases from any licensed Registered Organization (medical dispensary) under medical-program pricing and the practitioner-determined 60-day supply.

Minor patients require a designated caregiver and additional documentation. Caregivers complete a separate application and New York State Police background check.

Reciprocity and visiting patients

New York's framework is dual-track for visitors with notable medical-program reciprocity:

• Adult-use: any visitor 21 or older with a government-issued photo ID may purchase from a licensed adult-use retailer under the 3 oz / 24 g caps.
• Medical: non-resident medical cardholders may purchase from New York medical dispensaries (Registered Organizations) under OCM reciprocity policy. The visitor presents the out-of-state card plus a government photo ID.

The medical-program tax preference (no excise tax) and clinical-pharmacy environment at Registered Organizations are accessible to visiting medical patients in New York, distinctive from most states that limit reciprocity to possession-only.

CAURD program and retail rollout

MRTA's social-equity framework prioritized justice-impacted applicants (individuals previously convicted of cannabis-related offenses, or their immediate family members) for early retail licenses through the Conditional Adult-Use Retail Dispensary (CAURD) program. The first legal recreational dispensary opened in December 2022 in Manhattan. Licensing-allocation litigation slowed the rollout substantially through 2023 and 2024.

By mid-2026, the rollout has accelerated, with hundreds of licensed adult-use retailers operating statewide. Several factors continued to shape the market: the parallel illicit and gray-market retail footprint that operated during the licensed-retail rollout delay; OCM's enforcement crackdown on unlicensed retailers beginning in 2024 (Operation Padlock to Protect); and the broader OCM licensing-category framework (microbusiness, retail, on-premises consumption, distribution).

Employment and workplace

New York provides notable employment protections under MRTA, with carve-outs:

• Off-duty use: Labor Law §201-d treats cannabis as a lawful product; employers generally may not discriminate against an employee for off-duty use that does not produce on-the-job impairment.
• Workplace impairment: employers retain authority to discipline employees for on-the-job impairment as reasonably documented.
• Safety-sensitive positions: narrower carve-out than in many states; employers must specifically establish on-the-job impairment.
• Federal contractor and DOT-regulated positions: federal drug-free workplace and DOT testing rules supersede state-level protection.
• Medical patient protection: medical patient status provides additional layered protection on top of the MRTA framework.
• Workers' compensation: post-incident testing positive for THC may affect benefits if impairment at the time of incident is established.

New York's employment-protection framework is among the more worker-favorable in the United States. The New York City Commission on Human Rights has issued additional guidance restricting pre-employment cannabis testing for most NYC positions.

Hemp-derived intoxicants

New York enacted comprehensive restrictions on hemp-derived intoxicating cannabinoids through OCM authority and subsequent legislation. Delta-8 THC, delta-9 THC from hemp, delta-10 THC, THC-O, HHC, and similar compounds are restricted to retail channels licensed under the cannabis framework. Hemp-derived products exceeding defined THC thresholds are not lawful for retail sale outside the licensed cannabis supply chain.

Expungement

MRTA authorized substantial expungement of low-level cannabis convictions. The New York Office of Court Administration has expunged hundreds of thousands of records since 2021. The 2019 partial expungement framework (under earlier decriminalization legislation) provided the procedural foundation.

Recent legislative and regulatory history

Notable developments:

• 2014: Compassionate Care Act enacted; medical program established with narrow enumerated conditions.
• 2019: Marihuana Regulation and Taxation Act precursor advanced (decriminalization expansion; partial expungement).
• 2021: MRTA enacted; Office of Cannabis Management and Cannabis Control Board established.
• 2022: OCM expansion of medical certification to practitioner-discretion standard; first CAURD licenses awarded.
• 2022: first licensed adult-use retail sales began December 29.
• 2023: licensing-allocation litigation slowed rollout; CAURD framework restructured.
• 2024: unlicensed retailer enforcement crackdown; retail rollout accelerated; adult-use home cultivation effective mid-2024.
• 2025-2026: continued legislative work on on-premises consumption pilots, microbusiness expansion, and license-category refinement.

The April 2026 federal Schedule III rescheduling order produced no immediate New York legislative response; OCM issued operator guidance noting that state-level licensing and compliance obligations are unchanged.

Federal context

Federal jurisdiction layers additional exposure on federal land, federal courthouses, military installations (West Point, Fort Drum, Naval Submarine Base New London-adjacent, Niagara Falls Air Reserve Station, Air National Guard installations), and interstate highways. Statue of Liberty National Monument, Fire Island National Seashore, Gateway National Recreation Area, Adirondack and Catskill Park (state-managed but adjacent federal lands), and substantial federal land at the Canadian border fall under federal jurisdiction where cannabis prohibition applies. JFK International, LaGuardia, Newark Liberty (in New Jersey but serving the NYC metro), and Stewart International airports apply TSA cannabis-contraband rules. I-87 (NYS Thruway), I-95, I-81, I-86, I-88, I-90, and I-684 corridors see active state-patrol activity. The Canadian border at the New York-Quebec and New York-Ontario crossings sees substantial US Customs and Border Protection cannabis-enforcement activity.